Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 2
2021 6
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Glucokinase is required for high-starch diet-induced β-cell mass expansion in mice.
Tsuchida K, Nakamura A, Miyoshi H, Yang K, Yamauchi Y, Kawata S, Omori K, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Seino Y, Terauchi Y, Atsumi T. Tsuchida K, et al. Among authors: kawata s. J Diabetes Investig. 2021 Sep;12(9):1545-1554. doi: 10.1111/jdi.13532. Epub 2021 Mar 30. J Diabetes Investig. 2021. PMID: 33638884 Free PMC article.
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study).
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Manda N, Kurihara Y, Aoki S, Atsumi T, Miyoshi H. Cho KY, et al. Among authors: kawata s. Diabetes Obes Metab. 2020 Mar;22(3):458-462. doi: 10.1111/dom.13879. Epub 2019 Oct 13. Diabetes Obes Metab. 2020. PMID: 31486230 Free PMC article. Clinical Trial.
Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Omori K, Tsuchida K, Miya A, Shigesawa I, Tsuchida K, Yanagiya S, Kameda H, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Nishimoto N, Atsumi T, Miyoshi H. Cho KY, et al. Among authors: kawata s. J Diabetes Investig. 2021 Aug;12(8):1417-1424. doi: 10.1111/jdi.13498. Epub 2021 Feb 5. J Diabetes Investig. 2021. PMID: 33421309 Free PMC article. Clinical Trial.
Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study).
Hashimoto-Kameda R, Cho KY, Nomoto H, Nakamura A, Omori K, Nagai S, Edagawa S, Kawata S, Takeuchi J, Kameda H, Kurihara Y, Aoki S, Atsumi T, Miyoshi H; LUNA Study Investigators. Hashimoto-Kameda R, et al. Among authors: kawata s. Diabetes Res Clin Pract. 2021 Oct;180:109069. doi: 10.1016/j.diabres.2021.109069. Epub 2021 Sep 23. Diabetes Res Clin Pract. 2021. PMID: 34563585 Free article. Clinical Trial.
Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
Miya A, Nakamura A, Cho KY, Kawata S, Nomoto H, Nagai S, Sugawara H, Taneda S, Tsuchida K, Omori K, Yokoyama H, Takeuchi J, Aoki S, Kurihara Y, Atsumi T, Miyoshi H. Miya A, et al. Among authors: kawata s. J Diabetes Investig. 2021 Aug;12(8):1395-1399. doi: 10.1111/jdi.13479. Epub 2021 Jan 21. J Diabetes Investig. 2021. PMID: 33325645 Free PMC article. Clinical Trial.
Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, blinded endpoint parallel-group comparison study.
Kameda R, Nomoto H, Cho KY, Kawata S, Omori K, Takeuchi J, Nagai S, Kurihara Y, Aoki S, Nakamura A, Atsumi T, Miyoshi H. Kameda R, et al. Among authors: kawata s. BMJ Open. 2020 Feb 6;10(2):e034883. doi: 10.1136/bmjopen-2019-034883. BMJ Open. 2020. PMID: 32034028 Free PMC article.
Favorable Effect of Pemafibrate on Insulin Resistance and β-Cell Function in Subjects with Type 2 Diabetes and Hypertriglyceridemia: A Subanalysis of the PARM-T2D Study.
Nomoto H, Kito K, Iesaka H, Oe Y, Kawata S, Tsuchida K, Yanagiya S, Miya A, Kameda H, Cho KY, Sakuma I, Manda N, Nakamura A, Atsumi T. Nomoto H, et al. Among authors: kawata s. Pharmaceutics. 2023 Jun 27;15(7):1838. doi: 10.3390/pharmaceutics15071838. Pharmaceutics. 2023. PMID: 37514025 Free PMC article.